RhumbLine Advisers
BEAM icon

RhumbLine Advisers’s Beam Therapeutics BEAM Stock Holding History

RhumbLine Advisers’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.54M Buy
132,227
+19,988
+18% +$603K ﹤0.01% 1524
2026
Q1 		$2.67M Sell
112,239
-18,960
-14% -$526K ﹤0.01% 1712
2025
Q4 		$3.64M Sell
131,199
-12,629
-9% -$322K ﹤0.01% 1558
2025
Q3 		$3.49M Sell
143,828
-7,544
-5% -$150K ﹤0.01% 1606
2025
Q2 		$2.57M Buy
151,372
+10,168
+7% +$177K ﹤0.01% 1752
2025
Q1 		$2.76M Buy
141,204
+14,971
+12% +$392K ﹤0.01% 1651
2024
Q4 		$3.13M Sell
126,233
-872
-0.7% -$22.3K ﹤0.01% 1648
2024
Q3 		$3.11M Sell
127,105
-5,464
-4% -$141K ﹤0.01% 1665
2024
Q2 		$3.11M Buy
132,569
+23,565
+22% +$579K ﹤0.01% 1657
2024
Q1 		$3.6M Buy
109,004
+4,792
+5% +$149K ﹤0.01% 1596
2023
Q4 		$2.84M Sell
104,212
-1,284
-1% -$31.9K ﹤0.01% 1727
2023
Q3 		$2.54M Buy
105,496
+10,412
+11% +$279K ﹤0.01% 1746
2023
Q2 		$3.04M Buy
95,084
+7,136
+8% +$232K ﹤0.01% 1677
2023
Q1 		$2.69M Buy
87,948
+1,408
+2% +$55.6K ﹤0.01% 1655
2022
Q4 		$3.38M Buy
86,540
+1,583
+2% +$70.9K ﹤0.01% 1516
2022
Q3 		$4.05M Buy
84,957
+8,763
+12% +$500K 0.01% 1355
2022
Q2 		$2.95M Buy
76,194
+21,992
+41% +$874K ﹤0.01% 1551
2022
Q1 		$3.11M Buy
54,202
+2,389
+5% +$157K ﹤0.01% 1584
2021
Q4 		$4.13M Sell
51,813
-128
-0.2% -$11K 0.01% 1468
2021
Q3 		$4.52M Buy
51,941
+3,210
+7% +$322K 0.01% 1415
2021
Q2 		$6.27M Buy
48,731
+5,030
+12% +$401K 0.01% 1299
2021
Q1 		$3.5M Sell
43,701
-2,536
-5% -$241K ﹤0.01% 1608
2020
Q4 		$3.77M Buy
46,237
+9,204
+25% +$453K 0.01% 1518
2020
Q3 		$912K Buy
37,033
+22,386
+153% +$555K ﹤0.01% 2031
2020
Q2 		$410K Buy
14,647
+2,954
+25% +$63.7K ﹤0.01% 2434
2020
Q1 		$210K Buy
+11,693
New +$254K ﹤0.01% 2562

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

RhumbLine Advisers's BEAM Position: Q2 2026 in Review

RhumbLine Advisers increased its Beam Therapeutics (BEAM) stake by 18% in Q2 2026, buying an estimated $603K and bringing the position to 132,227 shares worth $4.54M. The position accounts for ﹤0.01% of the portfolio, ranked #1524.

RhumbLine Advisers first reported a position in BEAM in Q1 2020 and has held it in 26 quarters since. The position peaked at $6.27M in Q2 2021. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • RhumbLine Advisers held 132,227 shares of Beam Therapeutics worth $4.54M as of Q2 2026.
  • RhumbLine Advisers bought 19,988 Beam Therapeutics shares in Q2 2026, an estimated $603K.
  • Beam Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1524 holding.
  • RhumbLine Advisers first reported a position in Beam Therapeutics in Q1 2020 and has held it in 26 quarters since.
  • RhumbLine Advisers's Beam Therapeutics position peaked at $6.27M in Q2 2021.
  • 277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.